International Journal of Basic & Clinical Pharmacology (IJBCP) is an open access, international, peer-reviewed journal. The journal's full text is available online at http://www.ijbcp.com. The journal allows free access to its contents. IJBCP publishes important advances in pharmacology that include basic and clinical studies of all aspects of pharmacology in human, animal and cell-line studies. The journal also accepts articles on traditional medicine. The journal has a broad coverage of relevant topics across pharmacology including ethics, research methodology, data management, drug utilisation, regulatory, teaching and biostatistics. IJBCP is one of the fastest communication journals and articles are published online within short time after acceptance of manuscripts. The types of articles accepted include original research articles, review articles, case reports, conference abstracts, general articles in the field of basic and clinical pharmacology, new drug updates and letters to the editor. It is published every two months. IJBCP complies with the uniform requirements for manuscripts submitted to biomedical journals, issued by the International Committee for Medical Journal Editors. The complete document available at http://www.icjme.org.
The following types of manuscripts are routinely accepted (please note that word count is from abstract to references but excluding references):
Original articles: The form of these articles is discussed fully below; an abstract is required. They should be no longer than 4000 words and 40 references (as above, please note that word count also excludes tables, figures and legends).
Review articles: An abstract and keywords are required. The text should be divided into sections by suitable headings. Tables and figures may be used as appropriate for the text. They should be no longer than 5000 words.
Case reports: The journal welcomes adverse drug reaction reporting and interesting case reports pertaining to pharmacotherapy.
Meeting reports: Conference (pharmacology) reports can be submitted for publication.
Letters: Headings should not be used in a letter; no abstract or keywords are required. The text should be no more than 800 words; there should be a maximum of 10 references and one table or figure may be included.
New drug updates: Information on new drugs approved or under investigation can be published.
Commentaries: Commentaries are intended to put into context the material presented in a particular paper.
Correspondence: Correspondence is limited to specific comments or criticisms relating to a recent IJBCP paper, whose authors will be invited to reply.
It is strongly advised that Authors provide a list of 3 or 4 potential reviewers (e-mail and phone numbers) who are knowledgeable in the subject matter, have no conflict of interest, and are likely to agree to review the manuscript.
All authors should have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.
International Journal of Basic & Clinical Pharmacology (IJBCP) accepts manuscript submissions through eJournal Manager System. Clicking on the Submit a manuscript link (http://my.ejmanager.com/ijbcp/) on this page will open our manuscript submission service website.
Submit a manuscript (http://my.ejmanager.com/ijbcp/)
Alternatively authors may submit manuscript as an e-mail attachment to email@example.com / firstname.lastname@example.org. There is no need to send a hard copy. Submission of a manuscript implies that the work described has not been published before; that it is not under consideration for publication anywhere else; that its publication has been approved by all co-authors, if any. The IJBCP will not be held legally responsible should there be any claims for compensation.
Authors wishing to include figures, tables, or text passages that have already been published elsewhere are required to obtain permission from the copyright owner(s) for both the print and online format and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate from the authors.
Please ensure that the following are including in your submission:
1. One author designated as corresponding author: Their E-mail address, Full postal address, Telephone numbers
2. Cover letter addressed to the Editor, introducing the manuscript and confirming that it is not being submitted concurrently elsewhere
3. Scanned copy of copyright form signed by each author
5. All figure captions
6. All tables (including title, description, footnotes)
7. All necessary files have been uploaded as attachments to the e-mail
8. Manuscript has been spell checked
9. All text pages have been numbered
10. References are in the correct format for this journal
11. All references mentioned in the Reference list are cited in the text and vice versa
12. Permission has been obtained for use of copyrighted material from other sources (including the Web)
Please type all pages with single spacing and wide margins on one side of the paper. Title page, abstract, tables, legends to figures and reference list should each be provided on separate pages of the manuscript.
Use a normal, plain font (e.g., 12-point Times New Roman) for text. The text should be in single-column format. Number the pages. Keep the layout of the text as simple as possible. In particular, do not use the options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. Do not embed 'graphically designed' equations or tables, but prepare these using the facility in Word or as a separate file in Excel. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. Do not prepare tables in Powerpoint. Do not import the figures into the text file but, instead, indicate their approximate locations directly on the manuscript.
To avoid unnecessary errors you are strongly advised to use the spellchecker.
The title page should include: the title, the name(s) and affiliation(s) of the author(s), an address for correspondence, and telephone numbers for editorial queries. Original and review articles should include an Abstract (a single paragraph) of no more than 250 words and 3-6 key words for abstracting and indexing purposes.
Please do not split the article into separate files (title page as one file, text as another, etc.). Do not allow your computer to introduce word splits and do not use a 'justified' layout. Please adhere strictly to the general instructions on style/arrangement and, in particular, the reference style of the journal. It is very important that you save your file in the standard format for the program you are using (Microsoft Word docx format or doc format). Please write your text in good English (American or British usage is accepted, but not a mixture of these).
Provide the following information in your submission (in the order given):
Original research papers
1. Manuscripts must be accompanied by a covering letter, introducing the manuscript and confirming that it is not being submitted concurrently elsewhere.
2. The Abstract should be no more than 250 words
3. The limit for the main body of the manuscript is 4000 words excluding references
4. There should not normally be more than 40 references
5. You must use Times New Roman, Font size 12, Single spaced throughout your manuscript
If your manuscript exceeds the above limits, and you are unable to reduce the size, please include a statement in your cover letter declaring that you have exceeded the limits and justify the reasons for doing so for the Editors' consideration. Manuscripts must include:
1. Title page
6. Discussion and conclusions
11. Figures and Legends
1. Title page
The title page should be paginated as page 1 of the manuscript. Title of article: Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
Author names and affiliations: The title page should include the names and addresses of authors. Generally for uniformity author names should be written as first name, middle name initial followed by family name, e.g. James Z. Miller. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name.
Corresponding author: Clearly indicate who is willing to handle correspondence at all stages of refereeing and publication, also post-publication. Ensure that telephone numbers (with country and area code) are provided in addition to the e-mail address and the complete postal address.
Present/permanent address: If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.
The abstract will be printed at the beginning of the paper. A concise and factual abstract is required (maximum length 250 words). The abstract should state briefly the purpose of the research, the principal results and major conclusions. Do not cite references in the abstract. Non-standard or uncommon abbreviations should be avoided in the abstract, but if essential they must be defined at their first mention in the abstract itself. The abstract must be organized under the following subject headings: Background: This must indicate why the study was performed, and what question it was intended to answer. Methods: This should state in outline what methods were used. Results: The main results relevant to the question addressed should be summarised. Conclusions: This should summarize the main inferences that follow from the results. Keywords. Immediately after the abstract, provide a maximum of 6 keywords. Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. Define abbreviations that are not standard in this field at their first occurrence in the article: in the abstract but also in the main text after it.
The introduction should give a short and clear account of the background of the problem and state the objectives of the work. Only previous work that has a direct bearing on the present problem should be cited.
The methods must be described in sufficient detail to allow the experiments to be interpreted and repeated by an experienced investigator. Where published methods are used, references should be given, together with a brief outline. The statistical tool used to analyze the data should be mentioned. The description of drugs, chemicals and other materials should include the names and brief address of the relevant suppliers. Drug names should be International Non-proprietary Names (INN). If a drug has no INN its full chemical name must be used. All procedures involving experimental animals or human subjects must accompany a statement on ethical approval from appropriate ethics committee.
Reports of randomized, controlled trials should follow the recommendations of the Consolidated Standards of Reporting Trials (CONSORT) statement.
Reporting guidelines for specific study designs:
Present your results in a logical sequence in the text, tables, and figures, giving the main or most important findings first. Do not repeat in the text all the data in the tables or figures; emphasize or summarize only important observations.
6. Discussion and Conclusions
The purpose of the discussion is to present a brief and pertinent interpretation of the results against the background of existing knowledge. Any assumptions on which conclusions are based must be stated clearly. The main conclusions should be conveyed in a final paragraph with a clear statement of how the study advances knowledge and understanding in the field.
Collate acknowledgements in a separate section at the end of the article and do not, therefore, include them on the title page, as a footnote to the title or otherwise. When the work included in a paper has been supported by a grant from any source, this must be indicated. A connection of any author with companies producing any substances or apparatus used in the work should be declared. All contributors who do not meet the criteria for authorship as defined above should be listed in an acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, writing assistance, or a department chair who provided only general support. Authors should disclose whether they had any writing assistance and identify the entity that paid for this assistance.
This information must also be inserted into your manuscript under the acknowledgements section with the headings below. If you have no declaration to make please insert the following statements into your manuscript:
Competing interests: None declared
Ethical approval: Not required
References should be numbered consecutively as they appear in the text. Reference citations in the text should be identified by numbers in superscript after the punctuation marks. All authors should be quoted for papers with up to six authors; for papers with more than six authors, the first six should be quoted followed by et al.
Garber A, Klein E, Bruce S, Sankoh S, Mohideen P. Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2006;8:156-63
O'Brien C. Drug addiction and drug abuse. In: Brunton LB, Lazo JS, Parker KL, eds.Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill; 2005: 607-629.
National Cancer Institute. Fact sheet: targeted cancer therapies, 2012. Available at http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted#q1. Accessed 9 June 2012.
Each table should be given on a separate page, paginated as part of the paper. Tables should be numbered consecutively with Arabic numerals and the number should be followed by a brief descriptive caption, occupying not more than two lines, at the head of the table (e.g. Table 1: Effect of drug on blood pressure). Tables should normally be self-explanatory, with necessary descriptions provided underneath the table. Each column should have a heading and the units of measurement should be given in parentheses in the heading. Footnotes to tables should be indicated by superscript lower-case letters (or asterisks for significance values and other statistical data) and included beneath the table body.
11. Figures and Legends
Authors are encouraged to use color to enhance the impact and clarity of figures. There is no charge for using color in International Journal of Basic & Clinical Pharmacology. For figures supplied in parts, please use A, B, C, etc. to label the panels or parts of the figure. Name your figure files with “Figure” and the figure number, e.g., Figure 1: Liver enzyme levels. For the best quality final product, it is highly recommended that you submit all of your artwork – photographs, line drawings, etc. - in an electronic format. Computer prepared images must be at a minimum of 300 dpi at the final publication size. Lower resolution will result in pixilation and poor quality images. These should be submitted as JPEG or TIFF.
Figure legends should be typed on a separate page of the main manuscript document. Legends should explain the figures in sufficient detail that, whenever possible, they can be understood without reference to the text. Legends, captions and labels should be consistent with terminology or nomenclature used in the text.
Review articles, Case reports, Commentaries and Correspondence
The same patterns as described for Original research papers, with respect to text style, figures, tables and references, apply also to other publication types. A summary (up to 250 words) is required for Reviews, although the subject headings stipulated for Original research paper summaries do not apply.
International Journal of Basic & Clinical Pharmacology (IJBCP) doesn't charge article submission and processing fee from the authors. IJBCP charges a publication fee of Rs. 2500 for Indian authors and $70 for Non-Indian authors. Individual publication fee waiver requests are considered on the grounds of hardship on a case-by-case basis. Publication fee has to be paid only if your article gets accepted for publishing. There are no colour figure charges and no publication fee for case reports, letters to the editor. IJBCP charges a publication fee for research and review articles.
Copyright transfer form
Submission of a manuscript implies that the work described has not been published before; that it is not under consideration for publication anywhere else; that its publication has been approved by all co-authors, if any, as well as by the responsible authorities - tacitly or explicitly - at the institution where the work has been carried out. The Journal or the publisher will not be held legally responsible should there be any claims for compensation. Authors will be asked to transfer copyright of the article to the IJBCP. If we are not publishing the paper, it releases its rights therein at the time the manuscript is rejected following the editorial/peer review or retracted by the authors. The corresponding author and all co-authors, signs a copyright transfer form at the time of submission of the manuscript. Copyright form can be downloaded from here
International Journal of Basic & Clinical Pharmacology-Copyright form
This is to declare that all of us are authors of the following manuscript titled “……………………………………………………………………………………………………………………………………………………………………………………………………………” and we hereby agree to the following:
1. We have participated sufficiently in contributing to the content of this work and take responsibility for its contents.
2. We have read the manuscript and we believe that the manuscript represents valid work. Neither this manuscript nor one with substantially similar content under our authorship has been published. The article is not under consideration for publication with any other journal.
3. We hereby transfer or assign all copyright ownership, including any and all rights incidental thereto, exclusively to the Journal, in the event that such work is published by the Journal.
4. We hereby indemnify the International Journal of Basic & Clinical Pharmacology against any claims made by other parties concerning the authorship of the article or rights to publish the article.
5. We have no conflict of interest/we have the following conflict of interest.
6. We give the rights to the corresponding author to make necessary changes or any correspondence with the journal on our behalf. He/She will act as the guarantor for the manuscript on our behalf.
7. If requested by the editors, we will provide the data or will cooperate fully in obtaining and providing the data on which the manuscript is based, for examination by the editors.
Authors’ Name Signature Date signed
Please send it by e-mail to email@example.com, firstname.lastname@example.org
(Submit scanned copy of copyright form along with the manuscript)